Pediatric interventional cardiology in the united states is dependent on the off-label use of medical devices

Congenital Heart Disease

Volumn 5, Issue 1, 2010, Pages 2-7

  Sutherell, Jamie S ^a   Hirsch, Russel ^a   Beekman, Robert H ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Cardiac devices; Interventional cardiology; Off Label; Pediatric cardiology

Indexed keywords

ARTICLE; BALLOON DILATATION; CATHETERIZATION; COIL EMBOLIZATION; DEVICE THERAPY; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; PEDIATRICS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAFETY; STENT; UNITED STATES;

BALLOON DILATATION; CARDIOLOGY SERVICE, HOSPITAL; CHILD, PRESCHOOL; DEVICE APPROVAL; EMBOLIZATION, THERAPEUTIC; GUIDELINE ADHERENCE; HEART CATHETERIZATION; HOSPITALS, PEDIATRIC; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROGRAM EVALUATION; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; SEPTAL OCCLUDER DEVICE; STENTS; TIME FACTORS; UNITED STATES;

EID: 75149151524     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2009.00364.x     Document Type: Article

References (25)

1. Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin Ther. 2008, 11:2133-2145.
2. Hsien L, Breddemann A, Frobel AK. Off-label drug use among hospitalised children: identifying areas with the highest need for research. Pharm World Sci. 2008, 30:497-502.
3. Jain SB, Bavdekar SB, Gogtay NJ, Sadawarte PA. Off-label drug use in children. Indian J Pediatr. 2008, 75:1133-1136.
4. Kumar P, Walker JK, Hurt KM. Medication use in the neonatal intensive care unit: current patterns and off-label use of parenteral medications. J Pediatr. 2008, 152:412-415.
5. Shah SS, Hall MH, Goodman DM. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007, 161:282-290.
6. Sturkenboom MCJM, Verhamme KMC, Nicolosi A. Drug use in children: cohort study in three European countries. Brit Med J. 2008, 337:a2245.
7. Tafuri G, Trotta F, Leufkens HGM. Off-label use of medicines in children: can available evidence avoid useless pediatric trials? Eur J Clin Pharmacol. 2009, 65:209-216.
8. Eiland LS, Knight P. Evaluating the off-label use of medications in children. Am J Health-Syst Pharm. 2006, 63:1062-1065.
9. Schirm E, Tobi H, de Jong-van den Berg LTW. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics. 2003, 111:291-295.
10. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006, 166:1021-1026.
11. Tabbarock A. From off-label prescribing towards a new FDA. Med Hypotheses. 2009, 72:11-13.
12. Shim D, Fedderly RT, Beekman RH. Follow-up of coil occlusion of patent ductus arteriosus. J Am Coll Cardiol. 1996, 28:207-211.
13. Magee AG, Huggon IC, Seed PT, Qureshi SA, Tynan M. Transcatheter coil occlusion of the arterial duct; results of the European Registry. Eur Heart J. 2001, 22:1817-1821.
14. Wang JK, Liau CS, Huang JJ. Transcatheter closure of patent ductus arteriosus using Gianturco coils in adolescents and adults. Catheter Cardiovasc Interv. 2002, 55:513-518.
15. Gudausky TM, Hirsch R, Khoury PR, Beekman RH. Comparison of two transcatheter device strategies for occlusion of the patent ductus arteriosus. Catheter Cardiovasc Interv. 2008, 72:675-680.
16. McElhinney DB, Bergersen L, Marshall AC. In situ fracture of stents implanted for relief of pulmonary arterial stenosis in patients with congenitally malformed hearts. Cardiol Young. 2008, 18:405-414.
17. Breinholt JP, Nugent AW, Law MA, Justino H, Mullins CE, Ing FF. Stent fractures in congenital heart disease. Catheter Cardiovasc Interv. 2008, 72:977-982.
18. Barriers to the availability of medical devices intended for the treatment or diagnosis of diseases and conditions that affect children. U.S. Department of Health and Human Services and Food and Drug Administration, Report to Congress: October 2004
19. Holzer R, Hijazi Z. The off- versus on-label use of medical devices in interventional cardiovascular medicine: clarifying the ambiguity between regulatory labeling and clinical decision-making, part III: structural heart disease interventions. Catheter Cardiovasc Interv. 2008, 72:848-852.
20. Ansel GM, Jaff MR. The " art" of medicine and the " smokescreen" of the randomized trial off-label use of vascular devices. Catheter Cardiovasc Interv. 2008, 72:998-1002.
21. Price MJ, Teirstein PS. The off- versus on-label use of medical devices in interventional cardiovascular medicine: clarifying the ambiguity between regulatory labeling and clinical decision-making, part I: PCI. Catheter Cardiovasc Interv. 2008, 72:500-504.
22. Grines CL. Off-label use of drug-eluting stents putting it in perspective. J Am Coll Cardiol. 2008, 51:607-614.
23. Russel ME, Friedman MI, Mascioli SR, Stolz LE. Off-label use: an industry perspective on expanding use beyond approved indications. J Interv Cardiol. 2006, 19:432-438.
24. Stafford RS. Regulating off-label drug use-Rethinking the role of the FDA. NEJM. 2008, 358:1427-1429.
25. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationAndGuidance/ Overview/MedicalDeviceUserFeeAndModernizationActMDUFMA/UCM109100.pdf, Pediatric Medical Device Safety and Improvement Act of 2007, Available at Accessed October 27, 2009